2026年基於人工智慧（AI）的新型藥物設計全球市場報告

近年來，人工智慧（AI）在全新藥物發現領域的市場發展迅速。預計該市場規模將從2025年的19億美元成長到2026年的25.3億美元，複合年成長率（CAGR）高達33.4%。成長要素包括傳統藥物研發成本高昂、對更快藥物開發的需求日益成長、計算化學工具的廣泛應用、製藥業投資的增加以及學術界和科研機構合作的加強。

未來幾年，人工智慧（AI）在藥物發現領域的市場預計將迎來顯著成長。預計到2030年，該市場將以33.7%的複合年成長率成長，達到80.7億美元。預測期內的成長要素包括：人工智慧驅動的先導化合物生成技術的日益普及、ADMET預測模型的廣泛應用、雲端和本地部署整合度的提升、模型開發和數據標註服務的擴展，以及製藥公司和生物技術公司之間合作的加強。預測期內的關鍵趨勢包括：雲端人工智慧平台的廣泛應用、對利用深度學習的藥物發現軟體的需求不斷成長、藥物發現流程中工作流程自動化程度的提高、分子性質預測工具的擴展，以及對特定治療領域應用的日益關注。

複雜疾病的日益普遍預計將加速人工智慧（AI）在全新藥物發現領域的市場成長。複雜疾病是遺傳、環境和生活方式等多種因素共同作用導致的健康問題，通常影響多個身體系統，需要先進的醫療照護和長期治療。不健康的生活方式會增加糖尿病、心血管疾病和某些癌症等慢性疾病的風險，從而導致複雜疾病盛行率上升。人工智慧（AI）透過處理複雜的生物資料集並預測有效的候選藥物，加速創新治療方法的發現，並應對與多因素和長期複雜疾病相關的挑戰。例如，截至2024年2月，總部位於瑞士的國際組織世界衛生組織（世衛組織）預測，2050年，新增癌症病例將超過3,500萬例，比2022年記錄的估計2,000萬例增加77%。因此，複雜疾病的日益普遍正在推動人工智慧（AI）在新藥發現領域的市場成長。

在人工智慧（AI）藥物發現領域，領先的公司正致力於開發創新解決方案，例如原生AI藥物發現平台，以加速新型小分子化合物的設計和最佳化。原生AI藥物發現平台是整合系統，它利用AI模型從零開始產生、預測和篩選新型分子，透過比傳統試驗法更快、更有效率地識別有前景的化合物，從而加速藥物發現進程。例如，2025年11月，美國生物技術公司Terray Therapeutics推出了EMMI（Experimentation Meets Machine Intelligence，實驗與機器智慧的融合），這是一個專為從頭小分子設計而設計的原生AI藥物發現平台。該平台整合了Terray Therapeutics專有的超緊湊型實驗硬體、高度自動化的實驗環境以及第三代化學特異性AI變壓器介面（COATI3）化學模型，能夠產生數百萬個新型分子，預測其效力，識別最有希望的候選藥物，並對其進行迭代最佳化。該平台的生成式人工智慧利用強化學習來提案可合成的分子，而其預測性人工智慧模型則能快速評估效力、選擇性、溶解度、代謝和清除率等特性。此外，其選擇人工智慧還能確定要合成哪些分子，與業界標準相比，可將時間和成本降低高達三分之一。 EMMI不僅適用於企業內部的免疫學項目，也適用於旨在開拓先前未開發的化學領域的策略夥伴關係，使其成為從頭藥物發現和設計領域的創新解決方案。

目錄

第1章執行摘要

第2章 市場特徵

• 市場定義和範圍
• 市場區隔
• 主要產品和服務概述
• 全球人工智慧驅動型新藥設計市場：吸引力評分及分析
• 成長潛力分析、競爭評估、策略適宜性評估、風險狀況評估

第3章 市場供應鏈分析

• 供應鏈與生態系概述
• 清單：主要原料、資源和供應商
• 主要經銷商和通路合作夥伴名單
• 主要最終用戶列表

第4章：全球市場趨勢與策略

• 關鍵科技與未來趨勢
  • 人工智慧和自主智慧
  • 生物技術、基因組學和精準醫療
  • 數位化、雲端運算、巨量資料、網路安全
  • 工業4.0和智慧製造
  • 擴展客製化資料擷取解決方案，以滿足小眾資料需求。
• 主要趨勢
  • 雲端人工智慧平台的廣泛應用
  • 對利用深度學習的藥物發現軟體的需求日益成長
  • 藥物研發工作流程自動化整合進展
  • 分子性質預測工具的擴展
  • 人們對將其應用於特定治療領域越來越感興趣。

第5章 終端用戶產業市場分析

• 製藥公司
• 生技公司
• 學術研究機構
• 受託研究機構
• 醫療保健研究所

第6章 市場：宏觀經濟情景，包括利率、通貨膨脹、地緣政治、貿易戰和關稅的影響、關稅戰和貿易保護主義對供應鏈的影響，以及 COVID-19 疫情對市場的影響。

第7章：全球策略分析架構、目前市場規模、市場對比及成長率分析

• 全球人工智慧驅動型新藥設計市場：PESTEL 分析（政治、社會、技術、環境、法律因素、促進因素和限制因素）
• 全球人工智慧（AI）驅動型新藥設計市場：規模、對比及成長率分析
• 全球人工智慧（AI）驅動的新藥設計市場表現：規模與成長，2020-2025年
• 全球人工智慧（AI）驅動的新型藥物設計市場預測：規模與成長，2025-2030年，2035年

第8章：全球市場總規模（TAM）

第9章 市場細分

• 按組件
• 軟體、服務
• 按治療區域
• 腫瘤學、神經系統疾病、感染疾病、心血管疾病、罕見疾病、代謝性疾病及其他治療領域
• 部署模式
• 本機部署、雲端部署
• 透過使用
• 標靶辨識、先導化合物生成、分子性質預測、吸收、分佈、代謝、排泄和毒性（ADMET 預測）及其他應用。
• 最終用戶
• 製藥公司、生物技術公司、學術和研究機構、受託研究機構以及其他最終用戶
• 細分：依類型：軟體
• 雲端軟體、本地部署軟體、機器學習軟體、深度學習軟體、分子建模軟體、數據分析軟體、工作流程自動化軟體
• 細分：依類型：服務
• 諮詢服務、整合服務、維護和支援服務、培訓和教育服務、託管服務、資料標註服務、模型開發服務

第10章 區域與國別分析

第11章 亞太市場

第12章：中國市場

第13章：印度市場

第14章：日本市場

第15章：澳洲市場

第16章：印尼市場

第17章：韓國市場

第18章 台灣市場

第19章 東南亞市場

第20章 西歐市場

第21章英國市場

第22章：德國市場

第23章：法國市場

第24章：義大利市場

第25章：西班牙市場

第26章：東歐市場

第27章：俄羅斯市場

第28章 北美市場

第29章：美國市場

第30章：加拿大市場

第31章：南美市場

第32章：巴西市場

第33章 中東市場

第34章：非洲市場

第35章 市場監理與投資環境

第36章：競爭格局與公司概況

• 人工智慧（AI）在新型藥物設計的應用市場：競爭格局與市場佔有率（2024年）
• 人工智慧（AI）在新型藥物設計市場的應用：公司評估矩陣
• 人工智慧（AI）在新型藥物設計的應用市場：公司概況
  • Schrodinger Inc.
  • XtalPi Holdings Ltd.
  • Owkin Inc.
  • Insilico Medicine Inc.
  • Recursion Pharmaceuticals Inc.

第37章 其他大型企業和創新企業

• Deep Genomics Inc., Iktos SA, Atomwise Inc., Terray Therapeutics Inc., Evogene Ltd., Genesis Therapeutics Inc., Insitro Inc., Verge Genomics Inc., DeepCure Inc., Cloud Pharmaceuticals Inc., Gero LLC, Chai Discovery Inc., Latent Labs Ltd., BioAge Labs Inc., Peptone Ltd.

第38章：全球市場競爭基準分析與儀錶板

第39章：預計進入市場的新創企業

第40章 重大併購

第41章 具有高市場潛力的國家、細分市場與策略

• 2030 年人工智慧驅動的新藥設計市場：提供新機會的國家。
• 2030年人工智慧（AI）在新型藥物設計市場的應用：提供新機會的細分領域
• 2030年人工智慧驅動的新藥設計市場：成長策略
  • 基於市場趨勢的策略
  • 競爭對手的策略

第42章附錄

Artificial intelligence (AI) for de novo drug design involves using machine learning and computational algorithms to generate novel molecular structures with targeted biological properties. It employs pattern recognition, predictive modeling, and optimization techniques to efficiently explore vast chemical spaces. AI-driven approaches accelerate the discovery of potential drug candidates while reducing reliance on conventional trial-and-error methods.

The primary components of artificial intelligence (AI) for de novo drug design include software and services. Software platforms leverage AI algorithms to accelerate drug discovery, including target identification and lead compound optimization. Therapeutic areas include oncology, neurological disorders, infectious diseases, cardiovascular diseases, rare diseases, metabolic disorders, and other indications. Deployment occurs via on-premises and cloud-based solutions, serving applications such as target identification, lead compound generation, molecular property prediction, absorption, distribution, metabolism, excretion, and toxicity (ADMET) prediction, and others, with end users including pharmaceutical companies, biotechnology firms, academic and research institutes, contract research organizations, and other sectors.

Tariffs on imported computational hardware, specialized AI processors, and molecular modeling software components are impacting the AI for de novo drug design market by increasing costs for software providers and research organizations. Segments such as cloud-based software and deep learning platforms, especially in North America, Europe, and Asia-Pacific, are most affected. While tariffs elevate operational expenses, they also incentivize domestic hardware production, regional software development, and innovation in cost-efficient AI drug design platforms, enhancing local capabilities and supply chain resilience.

The artificial intelligence (AI) for de novo drug design market research report is one of a series of new reports from The Business Research Company that provides artificial intelligence (AI) for de novo drug design market statistics, including artificial intelligence (AI) for de novo drug design industry global market size, regional shares, competitors with a artificial intelligence (AI) for de novo drug design market share, detailed artificial intelligence (AI) for de novo drug design market segments, market trends and opportunities, and any further data you may need to thrive in the artificial intelligence (AI) for de novo drug design industry. This artificial intelligence (AI) for de novo drug design market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The artificial intelligence (AI) for de novo drug design market size has grown exponentially in recent years. It will grow from $1.9 billion in 2025 to $2.53 billion in 2026 at a compound annual growth rate (CAGR) of 33.4%. The growth in the historic period can be attributed to high r&d costs in traditional drug discovery, growing demand for faster drug development, adoption of computational chemistry tools, increasing pharmaceutical investments, expansion of academic and research collaborations.

The artificial intelligence (AI) for de novo drug design market size is expected to see exponential growth in the next few years. It will grow to $8.07 billion in 2030 at a compound annual growth rate (CAGR) of 33.7%. The growth in the forecast period can be attributed to growing adoption of ai-driven lead compound generation, increasing use of admet prediction models, rising integration of cloud and on-premises deployment, expansion of model development and data annotation services, growing collaboration between pharmaceutical and biotech companies. Major trends in the forecast period include increasing adoption of cloud-based ai platforms, rising demand for deep learning-based drug design software, growing integration of workflow automation in drug discovery, expansion of molecular property prediction tools, rising focus on targeted therapeutic area applications.

The rising prevalence of complex diseases is projected to accelerate the growth of the artificial intelligence (AI) for the de novo drug design market moving forward. Complex diseases are health disorders resulting from a combination of genetic, environmental, and lifestyle influences, often affecting multiple body systems and requiring advanced or prolonged medical care. The prevalence of complex diseases is increasing due to unhealthy lifestyle behaviors, which heighten the likelihood of chronic conditions such as diabetes, cardiovascular disorders, and certain types of cancer. Artificial intelligence (AI) for de novo drug design advances the discovery of innovative therapies by processing complex biological datasets and forecasting effective drug candidates, thereby addressing the difficulties associated with multifactorial and long-term complex diseases. For instance, in February 2024, according to the World Health Organization, a Switzerland-based international organization, more than 35 million new cancer cases are anticipated by 2050, reflecting a 77% increase compared to the estimated 20 million cases recorded in 2022. Therefore, the rising prevalence of complex diseases is driving the growth of the artificial intelligence (AI) for de novo drug design market.

Key companies operating in the artificial intelligence (AI) for de novo drug design market are focusing on developing innovative solutions, such as artificial intelligence (AI)-native drug discovery platforms, to accelerate the design and optimization of novel small molecules. Artificial intelligence (AI)-native drug discovery platforms are integrated systems that use AI models to generate, predict, and select novel molecules from scratch, helping accelerate drug discovery by identifying promising compounds faster and more efficiently than traditional trial-and-error methods. For example, in November 2025, Terray Therapeutics, a US-based biotechnology company, launched EMMI (Experimentation Meets Machine Intelligence), an AI-native drug discovery platform specifically engineered for de novo small molecule design. It integrates Terray Therapeutics' proprietary ultra-miniaturized experimental hardware with a highly automated laboratory environment and the Chemistry-Oriented AI Transformer Interface, third generation (COATI3) chemistry foundation model, to generate millions of novel molecules, predict their potency, identify the most promising candidates, and iteratively refine them. The platform's generative AI leverages reinforcement learning to propose synthetically accessible molecules, while predictive AI models rapidly assess properties such as potency, selectivity, solubility, metabolism, and clearance, and the selection AI determines which molecules to synthesize to reduce time and cost by up to threefold compared to industry standards. EMMI has applications across internal immunology programs as well as strategic partnerships targeting previously unexplored chemical space, making it a transformative solution for de novo drug design.

In July 2023, BioNTech SE, a Germany-based biopharmaceutical technology company, finalized the acquisition of InstaDeep Ltd. for $549 million (€500 million). With this acquisition, BioNTech intended to reinforce and broaden its strategic capabilities in artificial intelligence-enabled drug discovery and development by incorporating advanced AI and machine learning technologies to speed up the creation of next-generation immunotherapies and vaccines. InstaDeep Ltd. is a UK-based technology company that focuses on delivering advanced artificial intelligence and machine learning solutions that facilitate de novo drug design.

Major companies operating in the artificial intelligence (AI) for de novo drug design market are Schrodinger Inc., XtalPi Holdings Ltd., Owkin Inc., Insilico Medicine Inc., Recursion Pharmaceuticals Inc., Deep Genomics Inc., Iktos SA, Atomwise Inc., Terray Therapeutics Inc., Evogene Ltd., Genesis Therapeutics Inc., Insitro Inc., Verge Genomics Inc., DeepCure Inc., Cloud Pharmaceuticals Inc., Gero LLC, Chai Discovery Inc., Latent Labs Ltd., BioAge Labs Inc., Peptone Ltd., Generate Biomedicines Inc.

North America was the largest region in the artificial intelligence (AI) for de novo drug design market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the artificial intelligence (AI) for de novo drug design market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the artificial intelligence (AI) for de novo drug design market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The artificial intelligence (AI) for de novo drug design market consists of revenues earned by entities by providing services such as molecular design and generation, target identification and validation, lead optimization, predictive modeling and simulation, data analysis and integration, and virtual screening. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Artificial Intelligence (AI) For De Novo Drug Design Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses artificial intelligence (ai) for de novo drug design market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for artificial intelligence (ai) for de novo drug design ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The artificial intelligence (ai) for de novo drug design market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Component: Software; Services
• 2) By Therapeutic Area: Oncology; Neurological Disorders; Infectious Diseases; Cardiovascular Diseases; Rare Diseases; Metabolic Disorders; Other Therapeutic Areas
• 3) By Deployment Mode: On-Premises; Cloud-Based
• 4) By Application: Target Identification; Lead Compound Generation; Molecular Property Prediction; Absorption, Distribution, Metabolism, Excretion, And Toxicity (ADMET Prediction); Other Applications
• 5) By End User: Pharmaceutical Companies; Biotechnology Companies; Academic And Research Institutes; Contract Research Organizations; Other End Users
• Subsegments:
• 1) By Software: Cloud Based Software; On Premise Software; Machine Learning Software; Deep Learning Software; Molecular Modeling Software; Data Analytics Software; Workflow Automation Software
• 2) By Services: Consulting Services; Integration Services; Maintenance And Support Services; Training And Education Services; Managed Services; Data Annotation Services; Model Development Services
• Companies Mentioned: Schrodinger Inc.; XtalPi Holdings Ltd.; Owkin Inc.; Insilico Medicine Inc.; Recursion Pharmaceuticals Inc.; Deep Genomics Inc.; Iktos SA; Atomwise Inc.; Terray Therapeutics Inc.; Evogene Ltd.; Genesis Therapeutics Inc.; Insitro Inc.; Verge Genomics Inc.; DeepCure Inc.; Cloud Pharmaceuticals Inc.; Gero LLC; Chai Discovery Inc.; Latent Labs Ltd.; BioAge Labs Inc.; Peptone Ltd.; Generate Biomedicines Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.

Table of Contents

1. Executive Summary

• 1.1. Key Market Insights (2020-2035)
• 1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
• 1.3. Major Factors Driving the Market
• 1.4. Top Three Trends Shaping the Market

2. Artificial Intelligence (AI) For De Novo Drug Design Market Characteristics

• 2.1. Market Definition & Scope
• 2.2. Market Segmentations
• 2.3. Overview of Key Products and Services
• 2.4. Global Artificial Intelligence (AI) For De Novo Drug Design Market Attractiveness Scoring And Analysis
  • 2.4.1. Overview of Market Attractiveness Framework
  • 2.4.2. Quantitative Scoring Methodology
  • 2.4.3. Factor-Wise Evaluation
• Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation
• 2.4.4. Market Attractiveness Scoring and Interpretation
• 2.4.5. Strategic Implications and Recommendations

3. Artificial Intelligence (AI) For De Novo Drug Design Market Supply Chain Analysis

• 3.1. Overview of the Supply Chain and Ecosystem
• 3.2. List Of Key Raw Materials, Resources & Suppliers
• 3.3. List Of Major Distributors and Channel Partners
• 3.4. List Of Major End Users

4. Global Artificial Intelligence (AI) For De Novo Drug Design Market Trends And Strategies

• 4.1. Key Technologies & Future Trends
  • 4.1.1 Artificial Intelligence & Autonomous Intelligence
  • 4.1.2 Biotechnology, Genomics & Precision Medicine
  • 4.1.3 Digitalization, Cloud, Big Data & Cybersecurity
  • 4.1.4 Industry 4.0 & Intelligent Manufacturing
  • 4.1.5 Internet of Things (IoT), Smart Infrastructure & Connected Ecosystems
• 4.2. Major Trends
  • 4.2.1 Increasing Adoption of Cloud-Based AI Platforms
  • 4.2.2 Rising Demand for Deep Learning-Based Drug Design Software
  • 4.2.3 Growing Integration of Workflow Automation in Drug Discovery
  • 4.2.4 Expansion of Molecular Property Prediction Tools
  • 4.2.5 Rising Focus on Targeted Therapeutic Area Applications

5. Artificial Intelligence (AI) For De Novo Drug Design Market Analysis Of End Use Industries

• 5.1 Pharmaceutical Companies
• 5.2 Biotechnology Companies
• 5.3 Academic And Research Institutes
• 5.4 Contract Research Organizations
• 5.5 Healthcare Research Laboratories

6. Artificial Intelligence (AI) For De Novo Drug Design Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Artificial Intelligence (AI) For De Novo Drug Design Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

• 7.1. Global Artificial Intelligence (AI) For De Novo Drug Design PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 7.2. Global Artificial Intelligence (AI) For De Novo Drug Design Market Size, Comparisons And Growth Rate Analysis
• 7.3. Global Artificial Intelligence (AI) For De Novo Drug Design Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
• 7.4. Global Artificial Intelligence (AI) For De Novo Drug Design Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Artificial Intelligence (AI) For De Novo Drug Design Total Addressable Market (TAM) Analysis for the Market

• 8.1. Definition and Scope of Total Addressable Market (TAM)
• 8.2. Methodology and Assumptions
• 8.3. Global Total Addressable Market (TAM) Estimation
• 8.4. TAM vs. Current Market Size Analysis
• 8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Artificial Intelligence (AI) For De Novo Drug Design Market Segmentation

• 9.1. Global Artificial Intelligence (AI) For De Novo Drug Design Market, Segmentation By Component, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Software, Services
• 9.2. Global Artificial Intelligence (AI) For De Novo Drug Design Market, Segmentation By Therapeutic Area, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Oncology, Neurological Disorders, Infectious Diseases, Cardiovascular Diseases, Rare Diseases, Metabolic Disorders, Other Therapeutic Areas
• 9.3. Global Artificial Intelligence (AI) For De Novo Drug Design Market, Segmentation By Deployment Mode, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• On-Premises, Cloud-Based
• 9.4. Global Artificial Intelligence (AI) For De Novo Drug Design Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Target Identification, Lead Compound Generation, Molecular Property Prediction, Absorption, Distribution, Metabolism, Excretion, And Toxicity (ADMET Prediction), Other Applications
• 9.5. Global Artificial Intelligence (AI) For De Novo Drug Design Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Pharmaceutical Companies, Biotechnology Companies, Academic And Research Institutes, Contract Research Organizations, Other End Users
• 9.6. Global Artificial Intelligence (AI) For De Novo Drug Design Market, Sub-Segmentation Of Software, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Cloud Based Software, On Premise Software, Machine Learning Software, Deep Learning Software, Molecular Modeling Software, Data Analytics Software, Workflow Automation Software
• 9.7. Global Artificial Intelligence (AI) For De Novo Drug Design Market, Sub-Segmentation Of Services, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Consulting Services, Integration Services, Maintenance And Support Services, Training And Education Services, Managed Services, Data Annotation Services, Model Development Services

10. Artificial Intelligence (AI) For De Novo Drug Design Market Regional And Country Analysis

• 10.1. Global Artificial Intelligence (AI) For De Novo Drug Design Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• 10.2. Global Artificial Intelligence (AI) For De Novo Drug Design Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Artificial Intelligence (AI) For De Novo Drug Design Market

• 11.1. Asia-Pacific Artificial Intelligence (AI) For De Novo Drug Design Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 11.2. Asia-Pacific Artificial Intelligence (AI) For De Novo Drug Design Market, Segmentation By Component, Segmentation By Therapeutic Area, Segmentation By Deployment Mode, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Artificial Intelligence (AI) For De Novo Drug Design Market

• 12.1. China Artificial Intelligence (AI) For De Novo Drug Design Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 12.2. China Artificial Intelligence (AI) For De Novo Drug Design Market, Segmentation By Component, Segmentation By Therapeutic Area, Segmentation By Deployment Mode, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Artificial Intelligence (AI) For De Novo Drug Design Market

• 13.1. India Artificial Intelligence (AI) For De Novo Drug Design Market, Segmentation By Component, Segmentation By Therapeutic Area, Segmentation By Deployment Mode, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Artificial Intelligence (AI) For De Novo Drug Design Market

• 14.1. Japan Artificial Intelligence (AI) For De Novo Drug Design Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 14.2. Japan Artificial Intelligence (AI) For De Novo Drug Design Market, Segmentation By Component, Segmentation By Therapeutic Area, Segmentation By Deployment Mode, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Artificial Intelligence (AI) For De Novo Drug Design Market

• 15.1. Australia Artificial Intelligence (AI) For De Novo Drug Design Market, Segmentation By Component, Segmentation By Therapeutic Area, Segmentation By Deployment Mode, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Artificial Intelligence (AI) For De Novo Drug Design Market

• 16.1. Indonesia Artificial Intelligence (AI) For De Novo Drug Design Market, Segmentation By Component, Segmentation By Therapeutic Area, Segmentation By Deployment Mode, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Artificial Intelligence (AI) For De Novo Drug Design Market

• 17.1. South Korea Artificial Intelligence (AI) For De Novo Drug Design Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 17.2. South Korea Artificial Intelligence (AI) For De Novo Drug Design Market, Segmentation By Component, Segmentation By Therapeutic Area, Segmentation By Deployment Mode, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Artificial Intelligence (AI) For De Novo Drug Design Market

• 18.1. Taiwan Artificial Intelligence (AI) For De Novo Drug Design Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 18.2. Taiwan Artificial Intelligence (AI) For De Novo Drug Design Market, Segmentation By Component, Segmentation By Therapeutic Area, Segmentation By Deployment Mode, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Artificial Intelligence (AI) For De Novo Drug Design Market

• 19.1. South East Asia Artificial Intelligence (AI) For De Novo Drug Design Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 19.2. South East Asia Artificial Intelligence (AI) For De Novo Drug Design Market, Segmentation By Component, Segmentation By Therapeutic Area, Segmentation By Deployment Mode, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Artificial Intelligence (AI) For De Novo Drug Design Market

• 20.1. Western Europe Artificial Intelligence (AI) For De Novo Drug Design Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 20.2. Western Europe Artificial Intelligence (AI) For De Novo Drug Design Market, Segmentation By Component, Segmentation By Therapeutic Area, Segmentation By Deployment Mode, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Artificial Intelligence (AI) For De Novo Drug Design Market

• 21.1. UK Artificial Intelligence (AI) For De Novo Drug Design Market, Segmentation By Component, Segmentation By Therapeutic Area, Segmentation By Deployment Mode, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Artificial Intelligence (AI) For De Novo Drug Design Market

• 22.1. Germany Artificial Intelligence (AI) For De Novo Drug Design Market, Segmentation By Component, Segmentation By Therapeutic Area, Segmentation By Deployment Mode, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Artificial Intelligence (AI) For De Novo Drug Design Market

• 23.1. France Artificial Intelligence (AI) For De Novo Drug Design Market, Segmentation By Component, Segmentation By Therapeutic Area, Segmentation By Deployment Mode, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Artificial Intelligence (AI) For De Novo Drug Design Market

• 24.1. Italy Artificial Intelligence (AI) For De Novo Drug Design Market, Segmentation By Component, Segmentation By Therapeutic Area, Segmentation By Deployment Mode, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Artificial Intelligence (AI) For De Novo Drug Design Market

• 25.1. Spain Artificial Intelligence (AI) For De Novo Drug Design Market, Segmentation By Component, Segmentation By Therapeutic Area, Segmentation By Deployment Mode, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Artificial Intelligence (AI) For De Novo Drug Design Market

• 26.1. Eastern Europe Artificial Intelligence (AI) For De Novo Drug Design Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 26.2. Eastern Europe Artificial Intelligence (AI) For De Novo Drug Design Market, Segmentation By Component, Segmentation By Therapeutic Area, Segmentation By Deployment Mode, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Artificial Intelligence (AI) For De Novo Drug Design Market

• 27.1. Russia Artificial Intelligence (AI) For De Novo Drug Design Market, Segmentation By Component, Segmentation By Therapeutic Area, Segmentation By Deployment Mode, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Artificial Intelligence (AI) For De Novo Drug Design Market

• 28.1. North America Artificial Intelligence (AI) For De Novo Drug Design Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 28.2. North America Artificial Intelligence (AI) For De Novo Drug Design Market, Segmentation By Component, Segmentation By Therapeutic Area, Segmentation By Deployment Mode, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Artificial Intelligence (AI) For De Novo Drug Design Market

• 29.1. USA Artificial Intelligence (AI) For De Novo Drug Design Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 29.2. USA Artificial Intelligence (AI) For De Novo Drug Design Market, Segmentation By Component, Segmentation By Therapeutic Area, Segmentation By Deployment Mode, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Artificial Intelligence (AI) For De Novo Drug Design Market

• 30.1. Canada Artificial Intelligence (AI) For De Novo Drug Design Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 30.2. Canada Artificial Intelligence (AI) For De Novo Drug Design Market, Segmentation By Component, Segmentation By Therapeutic Area, Segmentation By Deployment Mode, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Artificial Intelligence (AI) For De Novo Drug Design Market

• 31.1. South America Artificial Intelligence (AI) For De Novo Drug Design Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 31.2. South America Artificial Intelligence (AI) For De Novo Drug Design Market, Segmentation By Component, Segmentation By Therapeutic Area, Segmentation By Deployment Mode, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Artificial Intelligence (AI) For De Novo Drug Design Market

• 32.1. Brazil Artificial Intelligence (AI) For De Novo Drug Design Market, Segmentation By Component, Segmentation By Therapeutic Area, Segmentation By Deployment Mode, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Artificial Intelligence (AI) For De Novo Drug Design Market

• 33.1. Middle East Artificial Intelligence (AI) For De Novo Drug Design Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 33.2. Middle East Artificial Intelligence (AI) For De Novo Drug Design Market, Segmentation By Component, Segmentation By Therapeutic Area, Segmentation By Deployment Mode, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Artificial Intelligence (AI) For De Novo Drug Design Market

• 34.1. Africa Artificial Intelligence (AI) For De Novo Drug Design Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 34.2. Africa Artificial Intelligence (AI) For De Novo Drug Design Market, Segmentation By Component, Segmentation By Therapeutic Area, Segmentation By Deployment Mode, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Artificial Intelligence (AI) For De Novo Drug Design Market Regulatory and Investment Landscape

36. Artificial Intelligence (AI) For De Novo Drug Design Market Competitive Landscape And Company Profiles

• 36.1. Artificial Intelligence (AI) For De Novo Drug Design Market Competitive Landscape And Market Share 2024
  • 36.1.1. Top 10 Companies (Ranked by revenue/share)
• 36.2. Artificial Intelligence (AI) For De Novo Drug Design Market - Company Scoring Matrix
  • 36.2.1. Market Revenues
  • 36.2.2. Product Innovation Score
  • 36.2.3. Brand Recognition
• 36.3. Artificial Intelligence (AI) For De Novo Drug Design Market Company Profiles
  • 36.3.1. Schrodinger Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.2. XtalPi Holdings Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.3. Owkin Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.4. Insilico Medicine Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.5. Recursion Pharmaceuticals Inc. Overview, Products and Services, Strategy and Financial Analysis

37. Artificial Intelligence (AI) For De Novo Drug Design Market Other Major And Innovative Companies

• Deep Genomics Inc., Iktos SA, Atomwise Inc., Terray Therapeutics Inc., Evogene Ltd., Genesis Therapeutics Inc., Insitro Inc., Verge Genomics Inc., DeepCure Inc., Cloud Pharmaceuticals Inc., Gero LLC, Chai Discovery Inc., Latent Labs Ltd., BioAge Labs Inc., Peptone Ltd.

38. Global Artificial Intelligence (AI) For De Novo Drug Design Market Competitive Benchmarking And Dashboard

39. Upcoming Startups in the Market

40. Key Mergers And Acquisitions In The Artificial Intelligence (AI) For De Novo Drug Design Market

41. Artificial Intelligence (AI) For De Novo Drug Design Market High Potential Countries, Segments and Strategies

• 41.1 Artificial Intelligence (AI) For De Novo Drug Design Market In 2030 - Countries Offering Most New Opportunities
• 41.2 Artificial Intelligence (AI) For De Novo Drug Design Market In 2030 - Segments Offering Most New Opportunities
• 41.3 Artificial Intelligence (AI) For De Novo Drug Design Market In 2030 - Growth Strategies
  • 41.3.1 Market Trend Based Strategies
  • 41.3.2 Competitor Strategies

42. Appendix

• 42.1. Abbreviations
• 42.2. Currencies
• 42.3. Historic And Forecast Inflation Rates
• 42.4. Research Inquiries
• 42.5. The Business Research Company
• 42.6. Copyright And Disclaimer